Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD1 | P21728 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747873 | 0.88 | ADRB2 (0.52) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2747176 | 0.87 | ADRB2 (0.67) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2747836 | 0.87 | ADRB2 (0.54) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2747829 | 0.86 | ADRB2 (0.40) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2748502 | 0.86 | ADRB2 (0.52) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2747650 | 0.85 | ADRB2 (0.50) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL13823368 | 0.82 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2747771 | 0.81 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2797338 | 0.81 | ADRB2 (0.54) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL2797423 | 0.81 | ADRB2 (0.54) | ADRB2ADRB1ADRB3DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.